Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Motaz Qadan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-6951-8308; OpenAlex author ID A5028867114. Sources: ClinicalTrials.gov.

Their work

Papers
58 (first author 3, last author 14)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
193
Papers, trials and grants by year

2018: 1 paper · 2019: 3 papers, 1 trial · 2020: 13 papers · 2021: 6 papers · 2022: 9 papers · 2023: 6 papers · 2024: 10 papers · 2025: 6 papers · 2026: 4 papers

Papers 50 of 58

  1. Neoadjuvant Chemotherapy With or Without Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2026.3716↗
  2. Neoadjuvant stereotactic body vs conventionally fractionated radiation therapy for borderline resectable and locally advanced pancreatic cancer: a propensity s… Co-author DOI 10.1016/j.gassur.2026.102358↗
  3. Lymph Node Yield Is Associated With Improved Overall Survival and Increased Time to Recurrence in Node-Negative Pancreatic Ductal Adenocarcinoma Following Neoa… Last author DOI 10.1097/sla.0000000000006432↗
  4. Actual Five-year Survival After Neoadjuvant Therapy and Resection for Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000007214↗
  5. Preoperative Biopsy Is Not Associated With Adverse Outcomes in Patients With Pancreatic Ductal Adenocarcinoma Undergoing Upfront Resection. Last author DOI 10.1016/j.jss.2025.01.007↗
  6. Prognostic factors for very early recurrence after neoadjuvant treatment and curative resection in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.surg.2025.109647↗
  7. Reappraising the Role of Intraoperative Neck Margin Revision in Postneoadjuvant Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Multi-institution… Co-author DOI 10.1097/sla.0000000000006322↗
  8. Efficacy of Neoadjuvant Therapy and the Prognostic Significance of Serum Carcinoembryonic Antigen Level in Patients with Localized Pancreatic Adenocarcinoma wi… Co-author DOI 10.1097/sla.0000000000006719↗
  9. Operation Alone for Resectable Pancreatic Adenocarcinoma: Should We Operate if Multimodal Treatment Is Off the Table? Last author DOI 10.1097/xcs.0000000000001464↗
  10. Molecular MRI of Dysregulated Zinc Secretion Detects Pancreatic Ductal Adenocarcinoma and Response to KRASG12D Inhibitor Treatment. Co-author DOI 10.1158/0008-5472.can-24-3384↗
  11. Common hepatic artery lymph node metastasis in pancreatic ductal adenocarcinoma: an analysis of actual survival. Co-author DOI 10.1016/j.gassur.2024.02.018↗
  12. Calcium channel blockers are associated with improved survival in pancreatic cancer patients undergoing neoadjuvant chemotherapy and resection. Co-author DOI 10.1016/j.hpb.2023.12.001↗
  13. Tumor Size Reduction and Serum Carbohydrate Antigen 19-9 Kinetics After Neoadjuvant FOLFIRINOX in Patients With Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1016/j.surg.2023.09.041↗
  14. The impact of surgical-oncologic textbook outcome in patients with stage I to III pancreatic ductal adenocarcinoma: A cross-validation study of two national re… Co-author DOI 10.1016/j.surg.2023.11.004↗
  15. Spatially resolved analysis of pancreatic cancer identifies therapy-associated remodeling of the tumor microenvironment. Co-author DOI 10.1038/s41588-024-01890-9↗
  16. Chemotherapy switch for localized pancreatic cancer: a systematic review and meta-analysis. Co-author DOI 10.1093/bjs/znae244↗
  17. The Revised R Status is an Independent Predictor of Postresection Survival in Pancreatic Cancer After Neoadjuvant Treatment. Co-author DOI 10.1097/sla.0000000000005874↗
  18. Feasibility, Safety, and Efficacy of Aggressive Multimodal Management of Elderly Patients With Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/sla.0000000000006131↗
  19. Dynamic Evolution of Fibroblasts Revealed by Single-Cell RNA Sequencing of Human Pancreatic Cancer. Co-author DOI 10.1158/2767-9764.crc-23-0489↗
  20. Collagen type I PET/MRI enables evaluation of treatment response in pancreatic cancer in pre-clinical and first-in-human translational studies. Co-author DOI 10.7150/thno.100116↗
  21. Smoking impairs the effect of neoadjuvant FOLFIRINOX on postresection survival in pancreatic cancer. Co-author DOI 10.1016/j.ejca.2023.113293↗
  22. Facility type is associated with improved perioperative and oncologic outcomes after minimally invasive surgery for pancreatic cancer. Last author DOI 10.1016/j.hpb.2023.04.010↗
  23. Underlying Bias in the Treatment of Pancreatic Cancer: Minorities Treated at the Same Facilities are Less Likely to Receive Neoadjuvant Therapy. Last author DOI 10.1097/sla.0000000000005354↗
  24. Tolerability, Attrition Rates, and Survival Outcomes of Neoadjuvant FOLFIRINOX for Nonmetastatic Pancreatic Adenocarcinoma: Intent-to-Treat Analysis. Last author DOI 10.1097/xcs.0000000000000499↗
  25. Disparities in Receipt of Adjuvant Therapy After Upfront Surgical Resection for Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1245/s10434-022-12976-1↗
  26. ASO Author Reflections: Addressing Racial Disparities in Pancreatic Cancer: How Can We Do Better? First author DOI 10.1245/s10434-023-13110-5↗
  27. Arterial involvement and resectability scoring system to predict R0 resection in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemor… Co-author DOI 10.1007/s00330-021-08304-y↗
  28. Pathological treatment response has different prognostic implications for pancreatic cancer patients treated with neoadjuvant chemotherapy or chemoradiotherapy. Co-author DOI 10.1016/j.surg.2021.10.015↗
  29. Development and validation of the Massachusetts General Hospital/Memorial Sloan Kettering nomogram to predict overall survival of resected patients with pancre… Last author DOI 10.1016/j.surg.2022.05.024↗
  30. Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment. Co-author DOI 10.1038/s41588-022-01134-8↗
  31. A Combination of Biochemical and Pathological Parameters Improves Prediction of Postresection Survival After Preoperative Chemotherapy in Pancreatic Cancer: Th… Co-author DOI 10.1097/sla.0000000000004143↗
  32. Reassessment of the Optimal Number of Examined Lymph Nodes in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000004552↗
  33. Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pancreatic Adenocarcinoma. First author DOI 10.1097/sla.0000000000004585↗
  34. Prediction of R Status in Resections for Pancreatic Cancer Using Simplified Radiological Criteria. Co-author DOI 10.1097/sla.0000000000005433↗
  35. ASO Research Letter: Trends in Location of Death for Individuals with Pancreatic Cancer in the United States. Last author DOI 10.1245/s10434-021-11058-y↗
  36. Influence of Klebsiella pneumoniae and quinolone treatment on prognosis in patients with pancreatic cancer. Co-author DOI 10.1002/bjs.12003↗
  37. Impact of PET/MRI in the Treatment of Pancreatic Adenocarcinoma: a Retrospective Cohort Study. Co-author DOI 10.1007/s11307-020-01569-7↗
  38. Conditional Survival in Resected Pancreatic Ductal Adenocarcinoma Patients Treated with Total Neoadjuvant Therapy. Co-author DOI 10.1007/s11605-020-04897-9↗
  39. Preoperative cholangitis is an independent risk factor for mortality in patients after pancreatoduodenectomy for pancreatic cancer. Co-author DOI 10.1016/j.amjsurg.2020.07.025↗
  40. Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy. Co-author DOI 10.1093/jnci/djaa073↗
  41. Intraoperative Radiation Mitigates the Effect of Microscopically Positive Tumor Margins on Survival Among Pancreatic Adenocarcinoma Patients Treated with Neoad… Co-author DOI 10.1245/s10434-020-09444-z↗
  42. Variation in long-term oncologic outcomes by type of cancer center accreditation: An analysis of a SEER-Medicare population with pancreatic cancer. Last author DOI 10.1016/j.amjsurg.2020.03.035↗
  43. Diabetes mellitus is associated with unfavorable pathologic features, increased postoperative mortality, and worse long-term survival in resected pancreatic ca… Co-author DOI 10.1016/j.pan.2019.10.007↗
  44. Clinical staging in pancreatic adenocarcinoma underestimates extent of disease. Last author DOI 10.1016/j.pan.2020.03.011↗
  45. Evaluation of Pathologic Response on Overall Survival After Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/mpa.0000000000001590↗
  46. Timing But Not Patterns of Recurrence Is Different Between Node-negative and Node-positive Resected Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003123↗
  47. Microscopic size measurements in post-neoadjuvant therapy resections of pancreatic ductal adenocarcinoma (PDAC) predict patient outcomes. Co-author DOI 10.1111/his.14067↗
  48. Pancreatic ductal adenocarcinoma: tumour regression grading following neoadjuvant FOLFIRINOX and radiation. Co-author DOI 10.1111/his.14086↗
  49. Pancreatic Adenocarcinoma: Unconventional Approaches for an Unconventional Disease. First author DOI 10.1158/0008-5472.can-19-2731↗
  50. Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targeted Molecular MRI. Co-author DOI 10.1158/1078-0432.ccr-18-1359↗

Trials 1

  1. Pilot Study of a Multimodal Prehabilitation Pancreatic Cancer Program Principal investigator NCT03865875↗

Closest collaborators

The 25 strongest of 193 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Keith D. Lillemoe · 44 shared papers, 2018–2026 · strength 6.57
  2. Cristina Rosa Ferrone · 33 shared papers, 2018–2026 · strength 4.40
  3. Carlos F. Fernandez-del Castillo · 29 shared papers, 2018–2025 · strength 4.11
  4. Theodore Sunki Hong · 22 shared papers, 2019–2026 · strength 3.07
  5. Jennifer Yon-Li Wo · 19 shared papers, 2019–2026 · strength 2.64
  6. Carlos Fernández-del Castillo · 16 shared papers, 2019–2026 · strength 2.60
  7. Andrew Louis Warshaw · 15 shared papers, 2018–2025 · strength 1.83
  8. David P. Ryan · 13 shared papers, 2019–2026 · strength 1.68
  9. Zhi Ven Fong · 8 shared papers, 2020–2026 · strength 1.65
  10. Lawrence Scott Blaszkowsky · 11 shared papers, 2019–2026 · strength 1.54
  11. Colin D. Weekes · 11 shared papers, 2019–2026 · strength 1.51
  12. Maximiliano Servín-Rojas · 6 shared papers, 2023–2026 · strength 1.36
  13. Louisa Bolm · 7 shared papers, 2020–2026 · strength 1.35
  14. Thomas P. Hank · 9 shared papers, 2020–2025 · strength 1.25
  15. Aparna R. Parikh · 8 shared papers, 2019–2024 · strength 1.02
  16. David Tsai Ting · 9 shared papers, 2019–2024 · strength 1.02
  17. Jon Michael Harrison · 7 shared papers, 2020–2026 · strength 1.02
  18. Roi Anteby · 3 shared papers, 2023–2025 · strength 0.95
  19. Theodoros P. Michelakos · 8 shared papers, 2019–2022 · strength 0.83
  20. Vikram Deshpande · 8 shared papers, 2019–2022 · strength 0.79
  21. Mari A. Mino-Kenudson · 6 shared papers, 2020–2024 · strength 0.74
  22. Guoliang Qiao · 4 shared papers, 2022–2025 · strength 0.73
  23. Oliver Strobel · 4 shared papers, 2022–2025 · strength 0.69
  24. Hannah Johnson Roberts · 4 shared papers, 2024–2026 · strength 0.66
  25. Giulio Belfiori · 3 shared papers, 2025–2026 · strength 0.62

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.